MEDICAL DEVELOPMENTS IN CANCER: AN EXAMINATION OF TULMIMETOSTAT

Cancer is a multifactorial disease characterized by uncontrolled cell proliferation and metastasis, often resulting in high mortality if untreated. Its pathogenesis is closely linked to genetic and epigenetic abnormalities, carcinogen exposure, and disruption of tumor suppressor gene activity. The Polycomb Repressive Complex 2 (PRC2), comprising EZH1 and EZH2 catalytic subunits, plays a critical role in gene silencing via histone H3 lysine 27 trimethylation (H3K27me3). Overactivation of EZH2 leads to silencing of tumor suppressor genes, thereby driving oncogenesis. By reducing H3K27me3 levels, Tulmimetostat reactivates tumor suppressor genes, inducing apoptosis, differentiation, and growth inhibition of cancer cells. Its dual activity provides an advantage over EZH2-only inhibitors by preventing resistance mechanisms mediated by compensatory EZH1 upregulation. Early clinical evidence indicates potential efficacy, particularly in ARID1A-mutant solid tumors. Common adverse effects include hematological toxicities such as neutropenia and thrombocytopenia, alongside gastrointestinal symptoms. Overall, Tulmimetostat represents a promising epigenetic therapy that targets histone methyltransferase activity, with the potential to enhance current cancer treatment strategies and expand therapeutic options for resistant tumors. Further ongoing trials will clarify its safety, efficacy, and role in combination regimens.